MOTS-c and drug testing: is it banned for athletes?

Last updated 2026-07-25

Is MOTS-c on WADA's banned substances list?

Not by that name, no. If you search the current World Anti-Doping Agency Prohibited List for the literal string "MOTS-c," you won't find it. That's true for 2024, and it's true going into 2025 versions as far as anyone can verify from public WADA documents. But absence of a name is a weak signal in anti-doping, and any athlete treating it as a green light is misreading how the list actually works. WADA's Prohibited List bans substances by class and by mechanism, more than by brand. Categories like "S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics" and "S4: Hormone and Metabolic Modulators" are written broadly on purpose, specifically to catch novel compounds that mimic the action of already-banned substances before they get individually named. MOTS-c is a mitochondrial-derived peptide that promotes metabolic homeostasis and improves insulin sensitivity in mouse models ^[1], which is exactly the kind of metabolic-modulator profile that S4 language is built to sweep in. So the honest answer is: no explicit ban today, but real exposure to a broad-category ban depending on how an anti-doping panel or lab interprets the substance's mechanism. If you're a tested athlete, that ambiguity itself is the risk, more than the peptide's biology. For background on the peptide's actual biology, see our MOTS-c overview.

Why would MOTS-c even be considered performance-enhancing?

Because the animal and cell data, while nowhere near human proof, is genuinely about the pathways doping regulators care about: insulin sensitivity, fat metabolism, and skeletal muscle function. The foundational 2015 Cell Metabolism paper found that mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mice ^[1]. A 2024 iScience paper found MOTS-c modulates skeletal muscle function by directly binding and activating CK2, a kinase involved in muscle signaling ^[2]. Separate work found MOTS-c reduces myostatin and muscle atrophy signaling in a 2021 study ^[3], and a 2022 Peptides paper found it promotes muscle differentiation in vitro ^[4]. A 2024 paper in the American Journal of Physiology found the peptide attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration, again in an animal model ^[5]. Stack those findings up and you get a peptide that, on paper, touches insulin sensitivity, muscle preservation, and anti-atrophy signaling all at once. That's a profile that reads like a performance enhancer's wish list, even though none of these effects have been demonstrated in a controlled human trial. The excitement is mechanistic and rodent-based. It is not clinical.

Does MOTS-c actually work like exercise, or is that just marketing?

It's marketing shorthand for a real but narrower finding, and the distinction matters if you're trying to reason about doping risk. MOTS-c is often called an "exercise mimetic" because it's classified under mitohormesis, the idea that mild mitochondrial stress (like exercise) triggers adaptive signaling. A 2022 review in Diabetes & Metabolism Journal covers MOTS-c specifically in the context of exercise and mitohormesis ^[6], and a 2021 review in Biochimica et Biophysica Acta looked at mitochondrial-derived peptides and exercise broadly ^[7]. These are legitimate mechanistic connections. Circulating MOTS-c levels do respond to exercise in some human studies referenced in that literature. What none of this shows is that injecting exogenous MOTS-c reproduces the full physiological effect of a training session in a human being. "Exercise in a pill" is a marketing phrase, not a study finding. The actual research shows a peptide that shares some signaling pathways with exercise-induced adaptation in mice and cells. Whether that translates to a measurable performance effect in a trained human athlete has not been tested in any published clinical trial we could find. That gap between mechanism and outcome is the whole story here, and it's worth sitting with rather than smoothing over.

Has MOTS-c been tested in human clinical trials for performance or metabolism?

Not that we could find, at least not in the peer-reviewed literature underlying most of the current interest. Every metabolic and muscle finding cited above (the insulin resistance work ^[1], the CK2 muscle signaling ^[2], the myostatin work ^[3], the atrophy studies ^[4][5]) comes from mouse models or cell culture. A 2023 Frontiers in Endocrinology review calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[8], which is the right way to describe early-stage research: promising, not proven, and not yet in humans for these indications. A 2023 Metabolites paper titled "MOTS-c Functionally Prevents Metabolic Disorders" is again rodent-based ^[9]. Even the disease-specific work, like the 2022 Pharmacological Research paper on MOTS-c relieving hyperglycemia and insulin resistance in gestational diabetes, is an animal model study ^[10], not a trial in pregnant patients. This pattern holds across essentially the entire published MOTS-c literature: strong mechanistic biology, zero human efficacy trials for metabolic or athletic outcomes as of this writing. A 2026 Sports Medicine paper specifically reviewing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is the closest thing to a direct assessment of MOTS-c in an athletic context ^[11], and it's a review of the therapy landscape, not a trial reporting new efficacy data on MOTS-c itself.

What would happen if MOTS-c showed up in a drug test?

Nobody outside an accredited anti-doping lab and WADA's own science committee can say with certainty how a positive MOTS-c finding would be adjudicated, and that uncertainty is itself a reason for caution. Here's what we can say. WADA-accredited labs run mass spectrometry panels that can detect many peptides and their metabolites, and new compounds get added to detection methods over time as labs develop reference standards. If MOTS-c or its metabolites turn up in a sample, the case would likely get argued under the broad S2 (peptide hormones and mimetics) or S4 (metabolic modulators) categories rather than under a MOTS-c-specific rule, since no such specific rule currently exists in the public list. That means the outcome would hinge on how the substance is characterized at hearing, which is a much worse position for an athlete than a clean bill of health. The practical takeaway: "it's not named on the list" is not legal advice, and it's not a safe harbor. Athletes bound by WADA, NCAA, or professional league testing programs should treat any unapproved research peptide, MOTS-c included, as a categorical risk until their sport's specific anti-doping authority says otherwise in writing.

Is MOTS-c legal to buy and use in the US?

It's legal to sell as a "research use only" chemical, but it is not an FDA-approved drug for any human use, and that distinction matters more than most sellers let on. MOTS-c does not appear in the Drugs@FDA database of approved drug products ^[12]. It also is not on the FDA's current list of bulk drug substances nominated for use in compounding under Section 503A ^[13], nor is it listed in the 21 CFR 216.23 final Bulks List ^[14] or the 21 CFR 216.24 Bulks List for 503B outsourcing facilities ^[15]. Compounding pharmacies operating under 21 U.S.C. 353a ^[16] are required to use bulk substances that appear on these lists (or meet other narrow criteria), so a compounder selling MOTS-c as a finished, dosed product for human use is operating outside that authorized structure, not inside it. What you'll actually find online is MOTS-c sold as a research chemical, often with a "not for human consumption" disclaimer that most buyers ignore. That's a real regulatory gray zone: legal to purchase as a lab reagent, not legal or FDA-sanctioned as a self-administered health product. If you want the compliance-relevant details on sourcing and quality variance, our dosage guide covers what's actually in these vials versus what's on the label.

What does the actual safety and efficacy evidence say about MOTS-c in athletes?

The most directly relevant paper is the 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance ^[11], which places MOTS-c in the broader unregulated-peptide category athletes are increasingly using off-label. That review's framing (approved versus unapproved) is the right lens: some peptides have real approved indications and dosing data, and MOTS-c is not one of them for any human athletic or metabolic use. Below is a rough sketch of what's actually been studied versus what's assumed:

That table is uncomfortable if you're hoping for a green light, but it's the honest state of the science. Every row with real evidence is preclinical. The row anyone actually cares about, safety and performance effect in trained humans, has no entry because no published trial fills it.

Does the FDA regulate MOTS-c the way it regulates approved drugs?

No, and that gap is exactly why quality and dosing are inconsistent across sellers. The FDA's own guidance on bulk drug substances used in compounding under Section 503A ^[17] lays out the legal pathway substances need to follow to be lawfully compounded into patient-specific prescriptions, and MOTS-c has not gone through it. FDA regulation under 21 CFR 201.128 also defines "intended use" based partly on labeling and marketing claims ^[18], which is why you'll see "not for human use" language on research-chemical listings even when the marketing around them clearly implies human self-administration. The practical effect for a buyer: there's no FDA-mandated purity standard, no required dosing consistency, and no adverse-event reporting infrastructure the way there is for an approved drug. Whatever's in the vial is whatever the specific supplier's quality control happens to catch, and third-party testing is inconsistent across the market. If you're going to use it despite that gap, working through a provider-reviewed pathway rather than an anonymous online seller at least puts a clinician between you and the syringe. MOTS-c Co reviews providers who work with compounding pharmacy partners for exactly this reason, though that review process is not the same thing as FDA approval and shouldn't be marketed as such.

What other health effects has MOTS-c research found outside of metabolism and muscle?

The research footprint is much wider than the exercise-mimetic conversation usually acknowledges, which is part of why the biology is genuinely interesting even without a human performance trial. MOTS-c has been studied in ovarian cancer, where a 2024 paper found it suppresses tumor progression by attenuating USP7-mediated LARS1 deubiquitination in cell and animal models ^[19]. It's been studied in lung injury: a 2025 Redox Biology paper found it attenuates lung ischemia-reperfusion injury via nuclear translocation and antioxidant gene activation ^[20], and a 2023 European Journal of Pharmacology paper found it suppresses ferroptosis in acute lung injury from myocardial ischemia reperfusion ^[21]. A 2023 Mitochondrion paper flagged it as a potential anti-pulmonary fibrosis factor ^[22], and a 2025 paper found it attenuates airway barrier dysfunction in allergic asthma models ^[23]. It's also been studied in bone metabolism ^[24], osteoarthritis cartilage degradation ^[25], hepatitis B antiviral mechanisms in a 2024 Gut paper ^[26], plasma membrane repair via TRIM72 translocation ^[27], gestational diabetes ^[10], diabetic cardiomyopathy (a 2025 review literally titled "Magical Molecule for Diabetic Cardiomyopathy?" ^[28], question mark very much intended by the authors), pancreatic islet cell senescence ^[29], and diabetic liver fibrosis where a 2025 Scientific Reports paper frames it as mimicking exercise to target the Keap1-Nrf2-Smad2/3 pathway ^[30]. Every single one of these is a cell or animal study. None is a human clinical trial. The breadth is real; the human translation is not there yet.

Is there a downside to taking a research peptide that isn't cleared or tested in humans?

Yes, and it's more than the doping angle. A 2018 Rejuvenation Research paper titled "Mitochondrial-Derived Peptides Exacerbate Senescence" is a reminder that this peptide family doesn't uniformly behave the way the pro-longevity narrative suggests ^[31]. That paper's title alone should temper any blanket claim that MOTS-c is simply good for aging cells across every context. Beyond biology, there's the sourcing problem. Because MOTS-c isn't on FDA's approved drug list ^[12] or its 503A/503B bulk substance lists ^[13][14][15], there's no standardized manufacturing oversight for the peptide sold online. Purity, concentration accuracy, and sterility all vary by supplier, and a contaminated or mis-dosed vial is a real injection-site infection and systemic risk regardless of what the peptide itself does. If you're going to research injection practices at all, our guides on injection sites and how to take MOTS-c at least cover the mechanical safety basics, separate from the doping question entirely.

What should a tested athlete actually do before considering MOTS-c?

Talk to your sport's anti-doping authority in writing before you touch it, not after. That's not a hedge, it's the only defensible move given the S2/S4 catch-all language problem described above. Beyond that: assume any positive test involving an unapproved peptide will be argued against you under the broadest applicable category, not in your favor. Assume there's no published human safety data to point to in your defense; the entire evidence base is mouse and cell work ^{[1][2][3][4][5][9][10]}. And assume the product itself, since it's unregulated, may not even contain what the label says. For a non-athlete researcher or clinician evaluating MOTS-c purely on the metabolic biology, the calculus is different and the MOTS-c dosage and dosage calculator pages cover what's typically used in research contexts. But for anyone subject to drug testing, the honest answer is that the interesting biology and the competitive risk are two separate conversations, and right now the second one has no clean resolution in writing from WADA.

Frequently asked questions

Is MOTS-c banned by WADA?

Not by name on the current Prohibited List, but it likely falls under broad categories like S2 (peptide hormones and mimetics) or S4 (metabolic modulators) given its effects on insulin sensitivity and muscle signaling. Absence of a specific name is not the same as being cleared for use by tested athletes.

Can MOTS-c be detected in a drug test?

WADA-accredited labs continually expand mass spectrometry panels to detect new peptides and their metabolites. Whether a specific test currently screens for MOTS-c isn't public information, and athletes shouldn't assume non-detection just because it's a newer research compound.

Is MOTS-c FDA approved?

No. MOTS-c does not appear in the Drugs@FDA database of approved products, and it's not on FDA's 503A or 503B bulk drug substance lists that govern lawful compounding. It's sold as a research chemical, not an approved therapeutic.

Does MOTS-c actually work like exercise in humans?

That claim is marketing shorthand for a narrower finding: MOTS-c shares some mitohormetic signaling pathways with exercise in mouse and cell studies, and circulating levels respond to exercise. No published human trial shows injecting MOTS-c reproduces exercise's physiological effects.

What does the 2015 Cell Metabolism study on MOTS-c actually show?

It found that MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, but the study was conducted in mice, not humans. It's the foundational metabolic paper in the field and is frequently over-generalized to human outcomes it didn't test.

Has MOTS-c been tested in any human clinical trials?

For metabolic or athletic performance outcomes, no published human clinical trial was identified in the current literature. Nearly all findings, including insulin sensitivity, muscle signaling, and anti-atrophy effects, come from rodent models or cell culture.

Why would MOTS-c be considered performance-enhancing at all?

Because animal studies link it to improved insulin sensitivity, reduced myostatin, muscle differentiation, and protection against muscle atrophy through direct CK2 activation. Those mechanisms overlap with what anti-doping bodies consider performance-relevant, even without human confirmation.

Is it legal to buy MOTS-c in the United States?

It's sold legally as a research-use-only chemical, but it's not FDA-approved for human use and isn't on the recognized compounding bulk substance lists. That's a gray zone: legal to purchase as a lab reagent, not sanctioned as a self-administered health product.

What happens if MOTS-c shows up in an athlete's sample?

There's no MOTS-c-specific rule to point to, so any case would likely be argued under broad categories covering peptide hormones and metabolic modulators. That ambiguity generally favors the testing authority, not the athlete, making the absence of a specific ban a weak defense.

Does MOTS-c have any approved medical use?

No. It has no FDA-approved indication and doesn't appear in the Drugs@FDA database. All current interest, across metabolic disease, cancer, lung injury, and bone health, stems from preclinical research, not approved clinical use.

Are there safety risks specific to MOTS-c beyond the doping question?

Yes. One 2018 study found that this peptide family can exacerbate senescence in certain contexts, complicating the simple 'anti-aging' narrative. There's also no standardized manufacturing oversight, so purity and dosing accuracy vary by supplier since it isn't FDA-regulated.

Should NCAA or professional athletes avoid MOTS-c entirely?

Given the lack of an explicit clearance, the broad catch-all doping categories it could fall under, and zero published human safety data, avoiding it until your sport's anti-doping authority provides written guidance is the only defensible position for a tested athlete.

Sources

1. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in a mouse model
2. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
3. PubMed, AJP Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
4. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
5. PubMed, AJP Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration in a mouse model
6. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review covering MOTS-c in the context of exercise and mitohormesis
7. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides and their relationship to exercise
8. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c described as a promising mitochondrial-derived peptide for therapeutic exploitation
9. PubMed, Metabolites 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in preclinical research
10. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes animal model
11. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
12. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
13. FDA, bulk drug substances nominated for compounding (current list): MOTS-c is not on FDA's current list of nominated bulk drug substances for 503A compounding
14. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the final Bulks List substances lawfully usable in 503A compounding, which MOTS-c is not on
15. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the Bulks List for 503B outsourcing facilities, which MOTS-c is not on
16. Cornell Law, 21 U.S.C. 353a (pharmacy compounding): Establishes the legal framework compounding pharmacies must follow, including bulk substance restrictions
17. FDA, bulk drug substances used in compounding under section 503A: FDA guidance on the legal pathway substances must follow for lawful compounding
18. eCFR, 21 CFR 201.128 (meaning of intended uses): Defines how intended use is determined partly by labeling and marketing claims
19. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination
20. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
21. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury from myocardial ischemia reperfusion
22. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor
23. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in allergic asthma models
24. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in the regulation of bone metabolism
25. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis models
26. PubMed, Gut 2024 (PMID 37788894): MOTS-c contributes to an antiviral role during HBV infection via mitochondrial remodeling
27. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation
28. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review questioning MOTS-c's role as a therapeutic molecule for diabetic cardiomyopathy
29. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in preclinical research
30. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise signaling to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3
31. PubMed, Rejuvenation Research 2018 (PMID 30058454): Mitochondrial-derived peptides can exacerbate senescence in certain contexts